---
layout: about
title: about
permalink: /

profile:
  align: right
  image: prof_pic.jpg
  image_circular: false # crops the image to make it circular
  more_info: >
    <div style="text-align: center; font-family: 'Times New Roman', serif; font-size: 15px;">
      1 Rue Laurent Fries, 67404 Illkirch, France
    </div>
    
  

selected_papers: true # includes a list of papers marked as "selected={true}"
social: true # includes social icons at the bottom of the page

announcements:
  enabled: true # includes a list of news items
  scrollable: true # adds a vertical scroll bar if there are more than 3 news items
  limit: 5 # leave blank to include all the news in the `_news` folder

latest_posts:
  enabled: true
  scrollable: true # adds a vertical scroll bar if there are more than 3 new posts items
  limit: 3 # leave blank to include all the blog posts
---

## About Me

I am a **Postdoctoral Fellow** in the [Molecular and Translational Oncology](https://www.igbmc.fr/) team at the **Institut de GÃ©nÃ©tique et de Biologie MolÃ©culaire et Cellulaire (IGBMC)** in Illkirch, France, working under the supervision of [Prof. Gabriel Malouf](https://scholar.google.com/citations?user=...).

My research focuses on leveraging **computational approaches** and **multi-omics integration** to understand cancer heterogeneity, predict treatment responses, and identify novel therapeutic targets. I am particularly interested in:

- **Cancer subtyping** using multi-omics data integration
- **Immunotherapy biomarkers** in renal cell carcinoma
- **Tumor microenvironment** characterization
- **Epigenetic regulation** of treatment resistance

---

## Research Highlights

### Multi-Omics Cancer Subtyping

I developed **[MOVICS](https://github.com/xlucpu/MOVICS)**, an R package for multi-omics integration and visualization in cancer subtyping. With **197 citations** and **144 GitHub stars**, MOVICS has become a widely-used tool in the cancer genomics community. The companion interactive platform **MOVICShiny** enables researchers to perform analyses without programming expertise.

### Immunotherapy Resistance in Kidney Cancer

My work on the **BIONIKK clinical trial** (NCT02960906) has identified epigenetic determinants of immunotherapy response in metastatic clear cell renal cell carcinoma. Key discoveries include:

- The **Tumor Enhancer Demethylation (TED)** phenotype associated with immune dysfunction
- The **Epigenetic Silencing Index (iMES)** predictive of primary resistance to immunotherapy
- **Angiogenic subtypes** that show enhanced response to combination immunotherapy

These findings, published in *Cell Reports Medicine*, *Clinical Cancer Research*, and *JITC*, provide actionable biomarkers for precision oncology.

### Rare and Pediatric Tumors

I have contributed to comprehensive molecular characterization of rare tumors including:
- **Upper tract urothelial carcinomas** (published in *Genome Biology*)
- **Anaplastic Wilms tumors** (published in *Nature Communications*)
- **Translocation renal cell carcinomas** (Rally Foundation funded)

---

## Scientific Contributions

<div class="row mt-3">
    <div class="col-sm-3 text-center">
        <h3 class="mb-0">54</h3>
        <p class="text-muted">Publications</p>
    </div>
    <div class="col-sm-3 text-center">
        <h3 class="mb-0">2,284</h3>
        <p class="text-muted">Citations</p>
    </div>
    <div class="col-sm-3 text-center">
        <h3 class="mb-0">21</h3>
        <p class="text-muted">h-index</p>
    </div>
    <div class="col-sm-3 text-center">
        <h3 class="mb-0">39</h3>
        <p class="text-muted">First Author</p>
    </div>
</div>

---

## Recent News

{% include news.liquid %}

---

## Featured Publications

{% include selected_papers.liquid %}

---

## Education

- **PhD in Bioinformatics** (2019-2022)  
  China Pharmaceutical University, Nanjing, China  
  *Thesis: Molecular Classification of Urothelial Carcinomas*

- **MSc in Biostatistics** (2016-2019)  
  China Pharmaceutical University, Nanjing, China

- **BSc in Medical Information Management** (2012-2016)  
  China Pharmaceutical University, Nanjing, China

---

## Contact

I am always open to research collaborations and discussions. Feel free to reach out:

ðŸ“§ **Email:** [lux@igbmc.fr](mailto:lux@igbmc.fr) | [xiaofan.lu@inserm.fr](mailto:xiaofan.lu@inserm.fr)  
ðŸ”¬ **ORCID:** [0000-0003-2417-6548](https://orcid.org/0000-0003-2417-6548)  
ðŸ’» **GitHub:** [xlucpu](https://github.com/xlucpu)

